Phase 2 clinical trial

Also known as: Phase 2 trial, Phase II trial, Phase 2b, proof-of-concept trial

A Phase 2 clinical trial is the stage of drug development that tests an investigational drug in patients with the target condition to gather early evidence of efficacy, identify the best dose and continue evaluating safety. It bridges the safety focus of Phase 1 and the large confirmatory trials of Phase 3.

How it works

Phase 2 studies usually enroll from several dozen to a few hundred patients. They are often split into:

Phase 2a: smaller proof-of-concept studies asking whether the drug has any effect.
Phase 2b: larger, often randomized and placebo-controlled studies comparing doses to choose the one for Phase 3.

Endpoints may be clinical outcomes or biomarkers. Many Phase 2 trials are randomized and blinded, but single-arm designs are common in oncology, where response rate is compared against historical benchmarks. Strong Phase 2 data can support breakthrough therapy designation and, in some cases, accelerated approval.

At the end of Phase 2, sponsors typically meet with the FDA to agree on the design of pivotal trials.

Why it matters for traders

Phase 2 is where many drugs fail, and it is often the most important readout for an early-stage biotech's valuation because it is the first real test of efficacy. Traders scrutinize:

Whether the trial hit its primary endpoint with statistical significance.
Effect size versus placebo and versus competing drugs.
Dose response, which supports that the effect is real.
Safety signals that could limit the commercial profile.

Example

Northwind Therapeutics (NWTX) runs a randomized Phase 2b in 240 patients across three doses and placebo (60 per arm). The high dose cuts disease flares by 50% versus placebo, the mid dose by 30%, and the low dose by 10%. The clean dose response supports moving the high dose into Phase 3.

Track it on Quantisnow

Related terms

Phase 1 clinical trialThe first stage of human testing for a new drug, focused on safety, tolerability, dosing and how the body processes it, usually in a small group.Phase 3 clinical trialThe large, late-stage trial that tests whether a drug works and is safe in a broad patient population, usually forming the basis for an FDA application.Topline dataThe first high-level results from a clinical trial, usually covering the primary endpoint and key safety findings, released before the full dataset.Primary endpointThe main outcome a clinical trial is designed and statistically powered to measure, used to judge whether the drug worked.Breakthrough therapy designationAn FDA designation that speeds development of a drug for a serious condition when early clinical data show substantial improvement over existing therapy.Accelerated approvalAn FDA pathway approving drugs for serious conditions based on a surrogate endpoint, with confirmatory trials required to verify clinical benefit.

Part of the Quantisnow financial glossary. For longer explainers, see the investing guides. Educational content, not investment advice.